NuGen Medical Devices Inc. (WKN: A3DABK) is revolutionizing the med-tech sector - shares severely undervalued despite an order volume of over $210 million!

NuGen Medical Devices Inc. (WKN: A3DABK) is revolutionizing the med-tech sector - shares severely undervalued despite an order volume of over $210 million!

According to a report from www.ariva.de, the med-tech company NuGen Medical Devices Inc. (WKN: A3DABK) has announced an order volume of over 210 million dollars, while the stock market valuation is only 25 million dollars. This is a clear indication of the company's enormous growth potential.

NuGen's InsuJet™ device, which aims to improve the care and lives of millions of people with diabetes, has entered into an agreement with Verrue Consulting Group BV in Belgium to revolutionize the Belgian diabetes market. The term of the distribution agreement is 5 years and the company estimates sales to be approximately $2.4 million.

Market analysis shows that the total market size in Belgium is 770,000 diabetics with type 1 diabetes, to whom sales will initially be targeted with a focus on InsuJet™.

This small med-tech startup created an order pipeline of over $210 million last year, which will have a significant impact on its balance sheets starting in fiscal year 2024.

It's not hard to see that the InsuJet™ is on its way to revolutionizing the diabetic world on every continent! Through this, the device eliminates the pain of the injection, the fear of needles and reduces the risk of infection.

NuGen Medical Devices Inc. (NASDAQ:NUGEN)'s valuation is very low compared to other companies in the med-tech space, signaling a huge growth opportunity. Since the company's gross margin is around 70%, this could lead to a significant increase in its stock market value.

Given the benefits of the InsuJet™ and the positive market outlook, this could be an attractive opportunity for investors. NuGen Medical Devices Inc. (WKN: A3DABK) stock is expected to show enormous potential for growth and success in the coming years.